Alzheimer s disease. The future of clinical trials: big problem, Big Data, big solution?
|
|
- Vincent Heath
- 6 years ago
- Views:
Transcription
1 Alzheimer s disease The future of clinical trials: big problem, Big Data, big solution?
2 The Problem More than 36m people with dementia Consumes 1% global GDP Serial trials failure
3 Targets for therapy
4 Nothing works! b secretase a secretase g secretase
5 January 2014
6 The solution Diversify target development More drugs! Trials in prodromal or preclinical disease Earlier treatment! Rapid trials with early read-outs Fail quicker!
7 Agenda What is Big Data? An integrated platform for translation Example studies Data driven proof of concept trials Data driven biomarkers for early detection Data driven experimental medicine Data driven mechanisms and drug discovery Looking forward
8 Big Data Volume
9 Big Data Variety
10 Big Data Velocity
11 Big Data Complexity
12 Too few targets; too slow progress Secondary prevention by 2025 Dementia research Institute ARUK Drug Discovery Institute Dementias Platform UK European Medical information Framework Translational Research Collaboration in Dementia European Prevention of Alzheimer s Disease Target identification Target development Trials ready cohorts and data Proof of concept trials Pre-competitive and collaborative
13 Too few targets; too slow progress Secondary prevention by 2025 Dementia research Institute ARUK Drug Discovery Institute Dementias Platform UK European Medical information Framework Translational Research Collaboration in Dementia European Prevention of Alzheimer s Disease Target identification Target development Trials ready cohorts and data Proof of concept trials
14 Prevention of Alzheimer s disease Secondary prevention Symptomatic therapy Adapted from Sperling et al (2011) Alzheimer s and dementia
15 EPAD Registry integration Cohort A Cohort B Cohort C Readiness cohort Selection criteria Trial cohort placebo Rx 1 Rx 2 Rx n Adaptation by change in intermediate phenotype Adaptation on cognition outcomes
16 Global Alzheimer s Prevention C-PAD? J-PAD US-PAD EPAD
17 The challenge of clinical trials volume variety velocity complexity Big data solution Add complexity : statistical modelling and dynamic trial design
18 Too few targets; too slow progress Secondary prevention by 2025 Dementia research Institute ARUK Drug Discovery Institute Dementias Platform UK European Medical information Framework Translational Research Collaboration in Dementia European Prevention of Alzheimer s Disease Target identification Target development Trials ready cohorts and data - Identification of biomarkers Proof of concept trials
19 Markers to enable secondary prevention Selection and stratification markers Secondary prevention Progression markers Symptomatic therapy Adapted from Sperling et al (2011) Alzheimer s and dementia
20 European Medical Information Framework
21 Biomarkers predicated on case-ness Systematic review of case-control blood based biomarkers for Alzheimer s disease 1 cohort; 109 proteins 21 studies, 3469 subjects 163 proteins Limited replication Methodological variation 6 cohorts; 4 proteins 4 cohorts; 6 proteins 3 cohorts; 6 proteins 2 cohorts; 38 proteins Kiddle et al. (2014) Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis 38 (3),
22 EMIF catalogue making data visible
23 Available research cohort data EMIF-AD Number of subjects Controls SCI MCI All Plasma DNA RNA CSF Urine MRI FDG-PET Amyloid PET EEG Either access to results from analysis or access to samples/scans
24 Stratification by pathology
25 Biomarkers predicated on in vivo pathology Study 1 In two independent cohorts FGG predicted PET amyloid burden Study 2 Training set (AIBL) Test set (UCSF) EMIF 500 n=500 FGG is significantly associated with CSF amyloid Study 3 Baltimore Longitudinal study of ageing FGG associated with PET amyloid
26 Biomarkers for secondary prevention of Alzheimer s the deep and frequent phenotyping study Aims to identify optimal set of markers for : patient stratification and selection for pre-clinical secondary prevention trials Markers of change for target engagement and early proof of concept trials Deep phenotyping Stratification markers Progression markers Adapted from Sperling et al (2011) Alzheimer s and dementia Molecular, imaging electrophysiology and cognitive markers Frequent phenotyping Approximately 2 month interval repeat measures Feasibility study Participant acceptability Multicentre practicability in the NIHR TRC-D
27 The challenge of biomarkers volume variety velocity complexity Big data solution Add volume : increase the size of studies Add complexity: combine different markers
28 Dementias Platform UK
29 UK Biobank Enhancements for Dementia Research Web-based questionnaires for additional exposures and outcomes (cognition, mental health, occupation..) Wrist-worn accelerometers mailed to 100,000 participants to measure physical activity Multimodal imaging in 100,000 Repeat Neuroimaging in 10,000 Genotyping of all participants (820,000 SNPs) Repeat cognition, samplling Connectivity to EMRs for mental health
30
31 Use of electronic medical records for research - Case Records Interactive Search (CRIS) SLaM CRIS South London and Maudsley NHS BRC implementation D-CRIS Cambridge & Peterborough, Oxford Health, West London, Camden and Islington 1 million plus patients UK-CRIS 10 site extension Connectivity to UK BioBank 2 million patients?
32 MMSE score EMR-data re-use for research (Donepezil/Arricept and Alzheimer s disease) Phase IV of ACHeI > 2500 patient years of therapy > 8 fold dataset compared to Cochrane Costs and effectiveness precompetitive collaboration with pharma Text mining derivation of service utilisation and costs Predictors of response Biomarkers and clinical time(years) Data from Robert Stewart, KCL
33 The challenge of mechanistic epidemiology volume variety velocity complexity Big data solution Add volume : massively deep and extensive testing Add variety : using coded (numbers) and narrative (text) data Add complexity : working across datatypes
34 Too few targets; too slow progress Secondary prevention by 2025 Dementia research Institute ARUK Drug Discovery Institute Dementias Platform UK European Medical information Framework Translational Research Collaboration in Dementia European Prevention of Alzheimer s Disease Target identification Target development Trials ready cohorts and data Proof of concept trials
35 Informatics driven targets JAK-STAT signalling common to Alzheimer s, macular degeneration and inflammatory disease JAK-STAT signalling correlates with risk Alejo Nevado-Holgado Proof of concept in experiments - In vitro and in vivo
36 Big Data and the dementia challenge? volume variety velocity complexity
37 Big Data challenges Data management Data analysis Data governance
38 Too few targets; too slow progress Secondary prevention by 2025 Dementia research Institute ARUK Drug Discovery Institute Dementias Platform UK European Medical information Framework Translational Research Collaboration in Dementia European Prevention of Alzheimer s Disease Target identification Target development Trials ready cohorts and data Proof of concept trials Big Data
39 With thanks to. 50 executive members 150 principal investigators 500 scientists 1500 collaborators 50,000 volunteers 50,000,000 individuals contributing data 200,000,000 euros from funders
40 Many thanks!
European Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationNIHR Supporting collaboration in life sciences research
NIHR Supporting collaboration in life sciences research Dr Matt Hallsworth - Head of External Relations, NIHR Office for Clinical Research Infrastructure (NOCRI) Research funders build capabilities and
More informationPositioning. > MEMENTO is a large observational study enrolling patients at an. Data first availability for project analyses
: determinants and Evolution of AlzheiMer s disease and related disorders ITMO Santé publique OVERVIEW AT A GLANCE Bordeaux Geneviève Chêne, MD, PhD Professor of Biostatistics and Public Health, Bordeaux
More informationDefeating dementia: progress and challenges on the road to 2025
Defeating dementia: progress and challenges on the road to 2025 Data sharing panel Moderator: Dr Steven Hyman Harvard University Distinguished Professor and Director, Stanley Center at the Broad Institute
More informationThe Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease
The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease AIBL: Two site collaborative study Study is conducted at two sites: Perth
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationDr Jeremy Parr, Neurodevelopment Disability and Lifecourse Research Group, Newcastle University Institute of Neuroscience
Dr Jeremy Parr, Neurodevelopment Disability and Lifecourse Research Group, Newcastle University Institute of Neuroscience https://research.ncl.ac.uk/neurodisability/ Jeremy.Parr@ncl.ac.uk Covering mental
More informationMaking dementia a European priority
Making dementia a European priority Glasgow 1 June 2015 Jean Georges, Executive Director Alzheimer Europe 36 associations in 31 countries 2 Paris Declaration Adopted by Annual General Meeting in Paris
More informationTranslational Research in Dementia
Translational Research in Dementia NOCRI simplifies access to the UK s world-leading clinical research infrastructure in Dementia through the NIHR Translational Research Collaboration Foreword Dementia
More informationThe summit and its purpose
Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to
More informationThe EME Programme. EME webinar Efficacy and Mechanism Evaluation Programme.
Efficacy and Mechanism Evaluation Programme EME webinar 2017 Where EME fits into UK biomedical research funding What will EME fund? What won t EME fund? The EME Programme vision The application/funding
More informationWelcome to today s webinar
Welcome to today s webinar We will begin the webinar at 2:00 p.m. Eastern All attendee lines are automatically muted. This webinar is being recorded and will be posted on LBDA s Youtube page. Throughout
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationFollowing the health of half a million participants
Following the health of half a million participants Cathie Sudlow UK Biobank Scientific Conference London, June 2018 Follow-up of participants in very large prospective cohorts Aim: identify a wide range
More informationUK Biobank: a large prospective cohort study into the causes of common complex diseases. Presentation to participants, 22 nd April 2015.
UK Biobank: a large prospective cohort study into the causes of common complex diseases. Presentation to participants, 22 nd April 2015. Overall strategy for UK Biobank resource 0.5M UK men and women aged
More informationResearch opportunities in UK Biobank
Research opportunities in UK Biobank Cancer Outcomes Conference June 2012 Cathie Sudlow Reader and Honorary Consultant Neurologist, University of Edinburgh Chief Scientist and Senior Epidemiologist, UK
More informationINTRODUCTION TO THE REMOTE ASSESSMENT OF DISEASE AND RELAPSE (RADAR) PROGRAMME
INTRODUCTION TO THE REMOTE ASSESSMENT OF DISEASE AND RELAPSE (RADAR) PROGRAMME All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationPaediatrics and Neuro-development MIC Theme 7
Brain Injury MedTech Co-operative Paediatrics and Neuro-development MIC Theme 7 Professor David Rowitch & Professor Topun Austin The is a partnership between the Cambridge University Hospitals NHS Foundation
More informationMASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER
MASSACHUSETTS ALZHEIMER S THE NEWSLETTER DISEASE RESEARCH OF THE CENTER Volume 1, Issue 4 Winter 2010 http://madrc.mgh.harvard.edu/ Mild Cognitive Impairment (MCI) A new look at early changes MASSACHUSETTS
More informationValue and challenges of combining large cohorts
Value and challenges of combining large cohorts Rory Collins UK Biobank Principal Investigator BHF Professor of Medicine & Epidemiology Nuffield Department of Population Health Richard Doll Building University
More informationBackground. In discussions of recruitment, the question was raised as to whether returning research results to subjects would help recruitment.
Alzheimer s Disease Neuroimaging Initiative Return of Research Results Working Group The REVEAL Study NHGRI/NIA Funded d 2000-2013 2013 Background In discussions of recruitment, the question was raised
More informationThe Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
More informationFlicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease
Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease Mojtaba Golzan (Research Fellow-Alzheimer s Australia) Department of Clinical Medicine, Macquarie University Ms. Dana Georgevsky
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationA Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing.
A Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing. Dean Hartley, Ph.D., Alzheimer's Association, Emily Drabant, Ph.D., 23 and me, Anne Wojcicki, 23 and me, Rob Fetherstonhaugh,
More informationAN INNOVATIVE APPROCH TOWARDS IDENTIFICAION OF NOVEL THERAPEUTIC DRUG TARGETS TO IMPROVE THE MANAGEMENT OF HEART FAILURE
AN INNOVATIVE APPROCH TOWARDS IDENTIFICAION OF NOVEL THERAPEUTIC DRUG TARGETS TO IMPROVE THE MANAGEMENT OF HEART FAILURE Cardiology, New solutions for drug development, Cutting-edge technologies, Multi-disciplinary
More informationCREATION OF A TORONTO CENTRE FOR DEMENTIA RESEARCH
CREATION OF A TORONTO CENTRE FOR DEMENTIA RESEARCH Barry D. Greenberg, Ph.D. Director, Neuroscience Drug Discovery and Development, UHN On behalf of the TDRA: Baycrest St. Michael s Hospital University
More informationReal world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform
Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform Catherine Reed, Lilly on behalf of ROADMAP consortium 3 rd Nordic conference on Real World Data, 28-29 November
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationAlzheimer s disease: the state of play
Alzheimer s disease: the state of play 30 th May 2012 Dr Eric Karran Director of Research ARUK Scope of presentation An overview of research into the causes of dementia, with an emphasis on Alzheimer s
More informationAlzheimer Europe Conference Berlin, 2-4 October Special Symposium 4 October, , Room II. Eli Lilly and Company
ENGAGING WITH PATIENT ORGANISATIONS WITHIN IMI CONSORTIA TO INFORM QUALITY, RELEVANCE AND VALUE IN ALZHEIMER S RESEARCH INSIGHTS FROM MOPEAD, EPAD AND ROADMAP Alzheimer Europe Conference Berlin, 2-4 October
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationExperimental Medicine Day Friday 28 March 2014 Institute of Psychiatry, King s College London 16 De Crespigny Park, London, SE5 8AF
Biomedical Research Centre for Mental Health and Dementia Unit at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King s College London Experimental Medicine Day Friday
More informationA New Genetic Test for Alzheimer s Disease and Dementia Risk with transformational potential
A New Genetic Test for Alzheimer s Disease and Dementia Risk with transformational potential A Polygenic Risk Score test for Alzheimer s Disease variatect TM and SNPfitR TM provide an accurate genetic
More informationInvolving research participants in research: The example of the EPAD (European Prevention of Alzheimer s Dementia) project
Involving research participants in research: The example of the EPAD (European Prevention of Alzheimer s Dementia) project Stina Saunders Alzheimer Europe Annual Conference Barcelona 2018 @stina_saunders
More informationTHE ICA INTEGRATED COGNITIVE ASSESSMENT TACKLING DEMENTIA WHEN IT COUNTS
THE ICA INTEGRATED COGNITIVE ASSESSMENT AI TACKLING DEMENTIA WHEN IT COUNTS 1 CONTENTS INTRODUCTION WHO WE ARE CURRENT ISSUES THE ICA BENEFITS MILESTONES MEDIA PRESCENCE 03 04 05 06 11 16 18 2 DEMENTIA
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationTOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION. Paul S. Aisen, MD Department of Neurosciences University of California, San Diego
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION Paul S. Aisen, MD Department of Neurosciences University of California, San Diego Brief History of AD Therapeutics 1906: Dr. Alois Alzheimer
More informationBGS Falls Severe mental illness, poor bone health and falls: The potential role for physical activity
Severe mental illness, poor bone health and falls: The potential role for physical activity Brendon Stubbs MCSP, PhD Head of Physiotherapy South London and Maudsley NHS Foundation Trust Post Doctoral Research
More informationChronic Effects of Neurotrauma Consortium (CENC)
Chronic Effects of Neurotrauma Consortium (CENC) 2013-2019 David X. Cifu, MD Senior TBI Specialist, U.S. Department of Veterans Affairs Associate Dean for Innovation and System Integrations, Virginia Commonwealth
More informationPROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS BACKGROUND Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) is
More informationCan aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators ASPREE Randomized, double-blind, placebo-controlled trial for extending healthy
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationDementia prevention in the 21 st century
Dementia prevention in the 21 st century Stina Saunders, MRes 10 th Scottish Caring & Dementia Congress April 2018 Dementia rates In the UK, one person every three minutes develops dementia that is 1 in
More informationClinical Trial Glossary
Clinical Trial Glossary Adverse event An unfavorable change in health that can occur during a clinical trial or study or within a certain time period after. These can range from mild (e.g., nausea) to
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationCYGNUS: A digital brain health platform for improving dementia outcomes
CYGNUS: A digital brain health platform for improving dementia outcomes Léa Marais - IXICO Hakim Yadi - Northern Health Science Alliance www.ecygnus.com Background to Cygnus Many people with dementia are
More informationGenetics and the prevention of CAD
Genetics and the prevention of CAD Presented by: Robert Roberts, MD, FRCPC, MACC, FAHA, FRSC Professor and Departmental Chair ISCTR University of Arizona College of Medicine Phoenix Past President and
More informationTreatments of tomorrow: dementia research and drug discovery. Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK
Treatments of tomorrow: dementia research and drug discovery Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK More failure What is different about dementia drug discovery? The
More informationHaving memory problems? Trouble thinking clearly? If this sounds like you, or someone you know, please consider the ENGAGE Study. Patient Information
Having memory problems? Trouble thinking clearly? If this sounds like you, or someone you know, please consider the ENGAGE Study Patient Information Why is the ENGAGE Study needed? There is an important
More informationUsing CART to Mine SELDI ProteinChip Data for Biomarkers and Disease Stratification
Using CART to Mine SELDI ProteinChip Data for Biomarkers and Disease Stratification Kenna Mawk, D.V.M. Informatics Product Manager Ciphergen Biosystems, Inc. Outline Introduction to ProteinChip Technology
More informationAdvances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017
Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide
More informationREPORT TO CONGRESS Multi-Disciplinary Brain Research and Data Sharing Efforts September 2013 The estimated cost of report or study for the Department of Defense is approximately $2,540 for the 2013 Fiscal
More informationEUROPEAN ADNI/PharmaCOG Papers in progress
EUROPEAN ADNI/PharmaCOG Papers in progress Journal Title 1st author *equally contributing authors Last author Status PLOS Medicine Development and validation of CSF cut-offs to predict progression in mild
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationImplementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
More informationDownloaded from:
Hemingway, H; Croft, P; Perel, P; Hayden, JA; Abrams, K; Timmis, A; Briggs, A; Udumyan, R; Moons, KG; Steyerberg, EW; Roberts, I; Schroter, S; Altman, DG; Riley, RD; PROGRESS Group (2013) Prognosis research
More informationAlzheimer s Disease Centers meeting San Diego, CA October 14, NIA-Division of Neurosciences update"
Alzheimer s Disease Centers meeting San Diego, CA October 14, 2017 NIA-Division of Neurosciences update" Eliezer Masliah, M.D. Director, Division of Neuroscience, National Institute on Aging, NIH AD grants
More informationTranslating Duke Health. Accelerating discovery and its translation
Translating Duke Health Accelerating discovery and its translation Translating Duke Health Biomedical discovery is accelerating innovative and revolutionary advancements in our understanding of human biology,
More informationThe 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationEXPERT CONSULTATION ON UNLOCKING GLOBAL COLLABORATION TO ACCELERATE INNOVATION FOR ALZHEIMER S DISEASE AND DEMENTIA.
EXPERT CONSULTATION ON UNLOCKING GLOBAL COLLABORATION TO ACCELERATE INNOVATION FOR ALZHEIMER S DISEASE AND DEMENTIA 20-21 June, 2013 The Harris Manchester College Oxford, United Kingdom Background The
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationResearch and possible future brain health treatments
Research and possible future brain health treatments Cheryl Brandi, DNSc, ARNP, NP-C Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 1 The Roskamp Institute Not for profit biomedical research
More informationILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet
ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet 03-04 July 2014, Milan, Italy Nutritional effects on cognitive ageing Trial data Dr. Ir. Ondine van
More informationPersonalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationConcept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
More informationBig Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit
Big Data & Predictive Analytics Case Studies: Applying data science to human data 1.03.2018 Big-Data.AI Summit Dr. Arnim Jost, Commercial Director Technology Copyright 2017 IQVIA. All rights reserved.
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationAnnotating Temporal Relations to Determine the Onset of Psychosis Symptoms
Annotating Temporal Relations to Determine the Onset of Psychosis Symptoms Natalia Viani, PhD IoPPN, King s College London Introduction: clinical use-case For patients with schizophrenia, longer durations
More informationAlzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationFunding research for the future
Funding research for the future Dr Helen Compton (helen.compton@nihr.ac.uk) Stakeholder Engagement Manager NIHR, Central Commissioning Facility The future of health and social care depends on today's research
More informationPotential Opportunities for Collaboration with Pancreatic U01s
Potential Opportunities for Collaboration with Pancreatic U01s Sudhir Srivastava, PhD, MPH Chief, Cancer Biomarkers Research Group Division of Cancer Prevention Background Recalcitrant Cancer Research
More informationNIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH
NIH HEAL Initiative: Program Update and Funding Opportunities for Pain Research Available through NIH AAMC Webinar November 8, 2018 Walter J. Koroshetz, MD Director, National Institute of Neurological
More informationCustom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationWatson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
More informationRare diseases: People, policy and practice. Dr Caroline Graham Office of Population Health Genomics
Rare diseases: People, policy and practice Dr Caroline Graham Office of Population Health Genomics Background Rare Diseases: People Policy Practice Rare Diseases: People Policy Practice Rare Diseases Individually
More informationNon-Pharmacological Strategies to Ameliorate Symptoms of Alzheimer s Disease and Related Dementia (NPSASA)
Non-Pharmacological Strategies to Ameliorate Symptoms of Alzheimer s Disease and Related Dementia (NPSASA) Competition objectives: The Alzheimer s Association is launching a new initiative to stimulate
More informationdrug discovery 8 9, 36, 42, 70, 73, , , 169, 172, , , 231, drug-induced liver injury (DILI) 93
Index ADNI see Alzheimer s Disease Neuroimaging Initiative adoption, clinical 90, 92 age-related macular degeneration (AMD) 148 49, 159, 161 AIDS vaccine 242, 250 51, 253 AIDS vaccine research 248 49,
More informationMRC Integrative Epidemiology Unit (IEU) at the University of Bristol. George Davey Smith
MRC Integrative Epidemiology Unit (IEU) at the University of Bristol George Davey Smith The making of a University Unit MRC Centre for Causal Analyses in Translational Epidemiology 2007 to 2013 Interdisciplinary
More informationJoint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference
More informationAdvance Research: Get Involved
John Brown, Sr. and Monica Parker, MD 2014 Research Opportunities with the ADRC Advance Research: Get Involved The Emory Alzheimer s Disease Research Center (ADRC) is one of 27 active centers in the nation
More informationResponse Ratio Female % Male % No Response(s) 1 <1 % Totals %
Constant Contact Survey Results Survey Name: Survey Questions for Researchers Status: Completed Filter: None Dec 03, 2008 1:30:39 PM What is your gender? Female 87 35.3 % Male 158 64.2 % No 1
More informationFDA Perspective on Disease Modification in Schizophrenia
FDA Perspective on Disease Modification in Schizophrenia Robert Levin, M.D. Clinical Team Leader Division of Psychiatry Products Food and Drug Administration Goals and Expectations Develop treatments that
More information